welcome
GlobalData

GlobalData

Health

Health

AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal

GlobalData
Summary
Nutrition label

83% Informative

AstraZeneca signs deal with CSPC Pharmaceuticals to research chronic disease drug candidates.

Deal worth up to $ 5.2bn with Chinese biotech company.

Deal is the second time this year Astra has invested resources in China .

Licensing deals between US and Chinese biopharma companies hit record highs last year .

VR Score

83

Informative language

83

Neutral language

48

Article tone

formal

Language

English

Language complexity

71

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

medium-lived

Affiliate links

no affiliate links